CN110520146A - 一种长效化突变的人源成纤维生长因子的新用途 - Google Patents

一种长效化突变的人源成纤维生长因子的新用途 Download PDF

Info

Publication number
CN110520146A
CN110520146A CN201880013016.2A CN201880013016A CN110520146A CN 110520146 A CN110520146 A CN 110520146A CN 201880013016 A CN201880013016 A CN 201880013016A CN 110520146 A CN110520146 A CN 110520146A
Authority
CN
China
Prior art keywords
alcoholic steatohepatitis
group
caused
use according
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880013016.2A
Other languages
English (en)
Inventor
李剑
韩君
马晓慧
太平
王根辈
曹小丹
黄瑞晶
金永杰
李静
陈晨
贾国勇
王媛媛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tasly Pharmaceutical Group Co Ltd
Original Assignee
Tasly Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tasly Pharmaceutical Group Co Ltd filed Critical Tasly Pharmaceutical Group Co Ltd
Publication of CN110520146A publication Critical patent/CN110520146A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明公开了一种长效化突变的人源成纤维生长因子的新用途，其中长效化突变的人源成纤维生长因子为脂糖素，其中所述新用途是在制备治疗非酒精性脂肪肝炎的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN201880013016.2A 2017-03-22 2018-03-19 一种长效化突变的人源成纤维生长因子的新用途 Pending CN110520146A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017101728240 2017-03-22
CN201710172824.0A CN108619490A (zh) 2017-03-22 2017-03-22 一种长效化突变的人源成纤维生长因子的新用途
PCT/CN2018/079482 WO2018171557A1 (zh) 2017-03-22 2018-03-19 一种长效化突变的人源成纤维生长因子的新用途

Publications (1)

Publication Number Publication Date
CN110520146A true CN110520146A (zh) 2019-11-29

Family

ID=63585053

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710172824.0A Pending CN108619490A (zh) 2017-03-22 2017-03-22 一种长效化突变的人源成纤维生长因子的新用途
CN201880013016.2A Pending CN110520146A (zh) 2017-03-22 2018-03-19 一种长效化突变的人源成纤维生长因子的新用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710172824.0A Pending CN108619490A (zh) 2017-03-22 2017-03-22 一种长效化突变的人源成纤维生长因子的新用途

Country Status (6)

Country Link
US (1) US20190367574A1 (zh)
EP (1) EP3603660A4 (zh)
JP (1) JP7491839B2 (zh)
CN (2) CN108619490A (zh)
CA (1) CA3049703A1 (zh)
WO (1) WO2018171557A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105601748B (zh) 2011-07-01 2021-08-27 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN105008548B (zh) 2012-12-27 2020-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态以及治疗胆汁酸紊乱和疾病的方法
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
CA3082794A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals Inc. Methods for treatment of bile acid-related disorders
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
CN108619490A (zh) * 2017-03-22 2018-10-09 天士力医药集团股份有限公司 一种长效化突变的人源成纤维生长因子的新用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103124562A (zh) * 2010-06-08 2013-05-29 诺沃—诺迪斯克有限公司 Fgf21的类似物和衍生物
CN103193878A (zh) * 2013-04-03 2013-07-10 哈尔滨博翱生物医药技术开发有限公司 突变hFGF-21蛋白成熟肽及其与聚乙二醇的交联物以及它们的应用
CN105792851A (zh) * 2013-09-13 2016-07-20 加州生物医学研究所 修饰的治疗剂及其组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1735340A2 (en) * 2004-03-17 2006-12-27 Eli Lilly And Company Glycol linked fgf-21 compounds
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
US20120172298A1 (en) * 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
JP2013533227A (ja) 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
EP2595647A1 (en) * 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal modified fgf21 compounds
CN101935346B (zh) 2010-08-24 2012-08-08 哈尔滨博翱生物医药技术开发有限公司 突变的人源成纤维生长因子及在治疗内分泌疾病中的用途
CN106255748A (zh) * 2014-02-24 2016-12-21 释放能量医药股份有限公司 诱导人褐色脂肪细胞祖细胞分化的方法和组合物
CN103923207B (zh) * 2014-04-08 2016-03-09 东北农业大学 一种fgf-21突变体蛋白的制备及其在治疗非酒精性脂肪肝中的应用
JP6702962B2 (ja) 2014-10-24 2020-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改変ｆｇｆ−２１ポリペプチドおよびその使用
CN108619490A (zh) * 2017-03-22 2018-10-09 天士力医药集团股份有限公司 一种长效化突变的人源成纤维生长因子的新用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103124562A (zh) * 2010-06-08 2013-05-29 诺沃—诺迪斯克有限公司 Fgf21的类似物和衍生物
CN103193878A (zh) * 2013-04-03 2013-07-10 哈尔滨博翱生物医药技术开发有限公司 突变hFGF-21蛋白成熟肽及其与聚乙二醇的交联物以及它们的应用
CN105792851A (zh) * 2013-09-13 2016-07-20 加州生物医学研究所 修饰的治疗剂及其组合物

Also Published As

Publication number Publication date
JP7491839B2 (ja) 2024-05-28
RU2019125343A (ru) 2021-02-09
WO2018171557A1 (zh) 2018-09-27
CN108619490A (zh) 2018-10-09
JP2020511545A (ja) 2020-04-16
EP3603660A4 (en) 2021-01-13
CA3049703A1 (en) 2018-09-27
EP3603660A1 (en) 2020-02-05
RU2019125343A3 (zh) 2021-03-31
US20190367574A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
CN110520146A (zh) 一种长效化突变的人源成纤维生长因子的新用途
JPH10504835A (ja) 胆汁酸塩および活性化合物の生物学的利用能を向上させる緩衝液を含む薬剤組成物
JP6853783B2 (ja) シリビンを含有する薬物組成物
AU2014305430B2 (en) Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof
EP2589382A1 (en) Pharmaceutical composition comprising levocarnitine and dobesilate
WO2020175817A1 (ko) 섬유증의 예방, 개선 또는 치료용 조성물
TWI776450B (zh) 正丁基苯酞於促進脂肪褐變、以及預防或治療脂肪肝及相關肝病變之應用
AU2018446089A1 (en) Pharmaceutical use of anemoside B4 against acute gouty arthritis
US20180030102A1 (en) Application of metrnl protein in preparing hypolipidemic, hypoglycemic medicine
RU2785582C2 (ru) Применение пегилированного рекомбинантного химерного фактора роста фибробластов-21 мыши или его фармацевтически приемлемой соли в составе лекарственных средств для лечения неалкогольного стеатогепатита
JPWO2019106851A1 (ja) 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）および／または非アルコール性脂肪性肝炎（ｎａｓｈ）、および／または肝脂肪性変性の治療と予防に適した、配合剤
KR100732614B1 (ko) 복어 추출물을 포함하는 비만 또는 당뇨성 질환의 예방또는 치료용 약학 조성물
EP3804705B1 (en) Pharmaceutical composition for preventing diabetes and use thereof
CN102526714B (zh) ***的药物组合物及其制备方法
CN110917209A (zh) 含硒化合物或硒纳米在制备治疗关节炎药物的注射剂或微针中的用途
CN114712427B (zh) 一种桃树根药物的应用
RU2803967C1 (ru) Медицинское применение анемозида b4 при лечении язв в полости рта
CN114569601B (zh) 新藤黄酸在制备预防和/或治疗肾脏病的药物中的应用
JP2014517057A (ja) 運動ニューロン疾患または代謝性疾患の治療のための直腸形態のフェニル酪酸塩
CN110507623B (zh) 一种含左甲状腺素钠的组合物及其应用
CN112826820B (zh) Nlrp3抑制剂及其应用
RU2718748C1 (ru) Способ коррекции метаболизма при риске развития жирового гепатоза у лактирующих коров
KR20080094466A (ko) 대사증후군 치료용 약제 조성물
CN116747226A (zh) 黄柏碱在制备治疗和/或预防非酒精性脂肪肝炎药物中的应用
CN112656794A (zh) 吡咯喹啉醌或其盐在制备用于防治***增生药物中的用途及药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination